KUALA LUMPUR, Nov 30 (Bernama) -- Adagio Therapeutics Inc, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialisation of antibody-based solutions for infectious diseases with pandemic potential, has provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron SARS-CoV-2 variant, and other known variants of concern.
ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralising activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year in a single injection.
“ADG20 was uniquely designed to combine breadth, potency and duration of protection against SARS-CoV-2 for up to one year in a single injection.
“We did this anticipating that SARS-CoV-2 would continue to evolve and potentially render some early therapies and vaccines obsolete,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio in a statement.
“Our global clinical trials are advancing with potential EUA submissions in mid-2022 for both prevention and treatment of COVID-19. We continue to engage with the FDA and other regulatory bodies and governmental agencies to discuss potential acceleration of development plans and the need for a portfolio of therapeutic solutions to combat the COVID-19 pandemic.”
Adagio co-founder and chief scientific officer Laura Walker, Ph.D said: “Due to the highly conserved and immunorecessive nature of the epitope recognised by ADG20, we expect that ADG20 will retain activity against Omicron, as we have observed in in vitro models with all other variants of concern identified previously.
Given the significant potential health crisis resulting from the emergence of Omicron, Adagio is undertaking a number of activities to support ADG20’s utility in addressing this newly emerged variant of concern, including conducting in vitro studies to evaluate the expected binding and neutralising activity of ADG20 against Omicron; and, recruiting patients in Adagio’s Phase 2/3 COVID-19 treatment trial, known as STAMP, across several clinical sites in South Africa to generate clinical data for ADG20 against infections due to the Omicron variant.
ADG20, an investigational monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is advancing through global clinical trials for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2.
For more information, visit www.adagiotx.com.
-- BERNAMA
No comments:
Post a Comment